Platin Analoglarının Klinik Kullanımları ve Yan Etki Yönetimleri
Özet
Platin analogları (sisplatin, karboplatin ve okzaliplatin), antineoplastik etkilerini DNA zincirinde kırıklar oluşturarak gösteren ve onkoloji pratiğinde tek başlarına, kombinasyon protokollerinde ya da radyoterapi ile eş zamanlı radyoduyarlaştırıcı olarak yaygın şekilde kullanılan ajanlardır. Birinci nesil analog olan sisplatin, adrenokortikal, baş-boyun, akciğer ve germ hücreli tümörler gibi geniş bir spektrumda kullanılmakta ancak yüksek emetojenik riski, %28-36 oranında görülebilen nefrotoksik yapısı ve kümülatif doza bağlı irreversibl ototoksik ile periferik nörotoksik yan etkileri nedeniyle sıkı GFR takibi ve agresif hidrasyon replasmanı gerektirmektedir. İkinci nesil karboplatin dozu, nefrotoksisiteyi azaltmak amacıyla Calvert formülü ve AUC hedefleri doğrultusunda GFR'ye göre hesaplanmakta olup, endometrium, akciğer ve over kanserlerinde tercih edilmekle birlikte doz sınırlayıcı temel yan etkisi belirgin miyelosupresyondur. Üçüncü nesil okzaliplatin ise çapraz direnç göstermeyen yapısıyla kolorektal, mide ve pankreas gibi gastrointestinal sistem malignitelerinde FOLFOX veya CAPOX gibi rejimlerle standart olarak yer almaktadır. Okzaliplatinin en spesifik ve sık görülen yan etkisi, soğuk tetikleyicilerle artan akut disestezi/paresteziler ile kümülatif doza bağlı olarak gelişen, yönetiminde duloksetin gibi ajanların kullanıldığı kronik duyusal nöropatidir. Ayrıca, bu ajanların doz yönetimleri hastanın ECOG performans durumuna, hematolojik tablosuna ve renal/hepatik fonksiyon modifikasyonlarına göre titizlikle sürdürülmektedir.
Platinum analogs (cisplatin, carboplatin, and oxaliplatin) are widely utilized antineoplastic agents in oncology practice that exert their therapeutic effects by inducing DNA strand breaks, administered either as monotherapy, in combination regimens, or concurrently with radiotherapy as radiosensitizers. Cisplatin, a first-generation analog, exhibits a broad spectrum of activity across various malignancies, including adrenocortical, head and neck, lung, and germ cell tumors; however, its clinical management requires stringent GFR monitoring and aggressive hydration due to a high emetogenic profile, a 28%-36% incidence of nephrotoxicity, and cumulative dose-dependent irreversible ototoxicity and peripheral neuropathy. The second-generation carboplatin, dosed precisely via the Calvert formula utilizing GFR and target AUC to minimize renal impairment, is commonly preferred in endometrial, lung, and ovarian cancers, with myelosuppression serving as its primary dose-limiting toxicity. Oxaliplatin, a third-generation analog, demonstrates no cross-resistance with prior generations and is established as a cornerstone in gastrointestinal malignancies (colorectal, gastric, and pancreatic cancers) via combination regimens such as FOLFOX or CAPOX. The most distinct toxicity of oxaliplatin is sensory neuropathy, presenting as cold-induced acute dysesthesias or cumulative dose-dependent chronic neuropathy managed with duloxetine, while overall dose adjustments for these platinum agents remain highly dependent on performance status, hematologic counts, and organic functions.
Referanslar
Chu E, T. DeVita V. Physicians Cancer Chemotherapy Drug Manual.; 2022.
UpToDate Cisplatin: Drug Information. Published 2022. Accessed October 11, 2022. https://www.uptodate.com/contents/cisplatin-drug-information?search=cisplatin&source=panel_search_result&selectedTitle=1~148&usage_type=panel&kp_tab=drug_general&display_rank=1
Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7
Plimack ER, Hoffman-Censits JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014;32(18):1895-1901. doi:10.1200/JCO.2013.53.2465
Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12(3):211-214. doi:10.1016/S1470-2045(10)70275-8
Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016;375(2):134-142. doi:10.1056/nejmoa1515725
Berger MJ, Anand S, Barbour S, et al. NCCN Guidelines Version 2.2022 Antiemesis Continue. Published online 2022. Accessed October 9, 2022. https://www.nccn.
Navari RM, Gray SE, Kerr AC. Olanzapine Versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized Phase III Trial. J Support Oncol. 2011;9(5):188-195. doi:10.1016/j.suponc.2011.05.002
Nakashima K, Murakami H, Yokoyama K, et al. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapyinduced nausea and vomiting in patients with thoracic malignancy. Jpn J Clin Oncol. 2017;47(9):840-843. doi:10.1093/jjco/hyx084
Reece PA, Stafford I, Russell J, Khan M, Gill PG. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol. 1987;5(2):304-309. doi:10.1200/JCO.1987.5.2.304
Motwani SS, McMahon GM, Humphreys BD, Partridge AH, Waikar SS, Curhan GC. Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin. J Clin Oncol. 2018;36(7):682-688. doi:10.1200/JCO.2017.75.7161
Suzuki Y, Kanazawa K, Kanai R, et al. A case of primary lung squamous cell carcinoma mimicking malignant mesothelioma producing granulocyte colony stimulating factor with chemotherapy (cisplatin and gemcitabine)-associated thrombotic thrombocytopenic purpura (TTP); An autopsy case report. Lung Cancer. 2019;136:105-108. doi:10.1016/J.LUNGCAN.2019.08.018
Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol. 2010;30(6):570-581. doi:10.1016/J.SEMNEPHROL.2010.09.005
Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD, Milowsky MI. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity. Oncologist. 2017;22(5):609-619. doi:10.1634/THEONCOLOGIST.2016-0319
Jordan B, Margulies A, Cardoso F, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(10):1306-1319. doi:10.1016/J.ANNONC.2020.07.003
Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020;38(28):3325-3348. doi:10.1200/JCO.20.01399
Albany C, Dockter T, Wolfe E, et al. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724). Support Care Cancer. 2021;29(2):833-840. doi:10.1007/S00520-020-05543-5
Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps - PubMed. Accessed October 11, 2022. https://pubmed.ncbi.nlm.nih.gov/2169332/
Glendenning JL, Barbachano Y, Norman AR, Dearnaley DP, Horwich A, Huddart RA. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer. 2010;116(10):2322-2331. doi:10.1002/CNCR.24981
Langer T, Am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O. Understanding platinum-induced ototoxicity. Trends Pharmacol Sci. 2013;34(8):458-469. doi:10.1016/J.TIPS.2013.05.006
Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748-1756. doi:10.1200/JCO.1989.7.11.1748
UpToDate. Carboplatin: Drug Information. Published 2022. Accessed October 16, 2022. https://www.uptodate.com/contents/carboplatin-drug-information?search=carboplatin&source=panel_search_result&selectedTitle=1~148&usage_type=panel&kp_tab=drug_general&display_rank=1#F50989309
Iihara H, Shimokawa M, Hayasaki Y, et al. Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study. Gynecol Oncol. 2020;156(3):629-635. doi:10.1016/J.YGYNO.2020.01.004
Tanaka K, Inui N, Karayama M, et al. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. Cancer Chemother Pharmacol. 2019;84(1):147-153. doi:10.1007/S00280-019-03868-5
Di Maio M, Baratelli C, Bironzo P, et al. Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2018;124:21-28. doi:10.1016/J.CRITREVONC.2018.02.001
UpToDate. Chemotherapy nephrotoxicity and dose modification in patients with kidney impairment: Conventional cytotoxic agents. Published 2022. https://www.uptodate.com/contents/chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-kidney-impairment-conventional-cytotoxic-agents?search=carboplatinrelatednephrotoxicity&source=search_result&selectedTitle=1~150&usage_type=default&disp
André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343-2351. doi:10.1056/NEJMOA032709
André T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol Off J Eur Soc Med Oncol. 2004;15(9):1339-1343. doi:10.1093/ANNONC/MDH351
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-1825. doi:10.1056/NEJMOA1011923
André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109-3116. doi:10.1200/JCO.2008.20.6771
Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet (London, England). 2012;379(9813):315-321. doi:10.1016/S0140-6736(11)61873-4
Synold TW, Takimoto CH, Doroshow JH, et al. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2007;13(12):3660-3666. doi:10.1158/1078-0432.CCR-06-2385
Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013;119(2):438-444. doi:10.1002/CNCR.27732
Pachman DR, Qin R, Seisler DK, et al. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). J Clin Oncol. 2015;33(30):3416-3422. doi:10.1200/JCO.2014.58.8533
Petrioli R, Pascucci A, Francini E, et al. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol. 2008;61(1):105-111. doi:10.1007/S00280-007-0454-3
Cassidy J, Misset J-L. Oxaliplatin-related side effects: characteristics and management. Semin Oncol. 2002;29(5 Suppl 15):11-20. doi:10.1053/SONC.2002.35524
de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938-2947. doi:10.1200/JCO.2000.18.16.2938
Bennett BK, Park SB, Lin CSY, Friedlander ML, Kiernan MC, Goldstein D. Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer. 2012;20(11):2959-2967. doi:10.1007/S00520-012-1428-5
Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020;38(28):3325-3348. doi:10.1200/JCO.20.01399
UpToDate. Oxaliplatin: Drug information. Published 2022. Accessed October 16, 2022. https://www.uptodate.com/contents/oxaliplatin-drug-information?search=oxaliplatin&source=panel_search_result&selectedTitle=1~148&usage_type=panel&kp_tab=drug_general&display_rank=1#F204234
Seo AN a., Kim H. Sinusoidal obstruction syndrome after oxaliplatin-based chemotherapy. Clin Mol Hepatol. 2014;20(1):81-84. doi:10.3350/CMH.2014.20.1.81
